Olopatadine HCL 0.1% Ophthalmic Solution

Amendment / Modification

• Option Year 3 of the contract SPE2D2-23-D-0007 is exercised.

• The period of performance for Option Year 3 is effective from February 15, 2026, through February 14, 2027.

• The exercise of Option Year 3 modifies the contract's period of performance.

• This modification exercises an option and does not appear to alter proposal submission deadlines or requirements for any future solicitations. All other terms and conditions of the original contract remain unchanged.

Amendment / Modification

This modification (P00007) updates the contract SPE2D2-23-D-0007, originally dated February 15, 2023.

Key changes include:

• Deletion of several solicitation provisions and contract clauses, including those related to:
  • Prohibition of Segregated Facilities
  • Equal Employment Opportunity
  • Affirmative Action Compliance
  • Compliance with Environmental Management Systems
  • Public Disclosure of Greenhouse Gas Emissions and Reduction Goals
• Revision of the following contract clauses:
  • FAR 52.223-10, Waste Reduction Program (DEVIATION 2025-00004)
  • FAR 52.223-23, Sustainable Products and Services (DEVIATION 2025-00004)
• Substitution of specific paragraphs within other provisions and clauses, including:
  • FAR 52.204-8, Annual Representations and Certifications
  • FAR 52.212-3, Offeror Representations and Certifications-Commercial Products and Commercial Services
  • FAR 52.212-5, Contract Terms and Conditions Required To Implement Statutes or Executive Orders-Commercial Products and Commercial Services
  • FAR 52.213-4, Terms and Conditions-Simplified Acquisitions
  • FAR 52.222-9, Apprentices and Trainees
  • FAR 52.244-6, Subcontracts for Commercial Products and Commercial Services

Multiple sections of the original solicitation and contract are affected, primarily related to equal opportunity, environmental compliance, and sustainable procurement. Specific FAR clauses and provisions have been deleted, revised, or substituted.

This modification primarily makes administrative and regulatory updates to the contract terms. It is crucial for the contractor to review these changes to ensure compliance. The modification states that if the contractor does not agree or is not in compliance, they must immediately notify the Contracting Officer in writing. Continued performance without notification will be considered acceptance of the modified terms.

Amendment / Modification

This modification (P00005) incorporates the clause 52.204-30, "Federal Acquisition Supply Chain Security Act Orders-Prohibition (DEC 2023)". This clause addresses the prohibition of certain "covered articles" or sources related to supply chain security, as defined by the Federal Acquisition Supply Chain Security Act (FASCSA).

• The entire contract is modified to include the new clause.

• Definitions for "Covered article," "FASCSA order," "Intelligence community," "National security system," and "Reasonable inquiry" are provided.

• The clause outlines prohibitions on providing or using covered articles or products/services from prohibited sources.

• It details procedures for searching SAM.gov for applicable FASCSA orders and for reporting potential impacts.

• Requirements for contractors to conduct reasonable inquiries and report findings to the contracting officer are specified.

• Provisions for requesting waivers and for removal of prohibited articles/services are included.

• The clause must be inserted into subcontracts.

• Contractors are required to review the new clause and ensure compliance.

• This may necessitate changes to their supply chain and reporting procedures.

• Contractors must acknowledge receipt of this amendment and comply with the new clause. Failure to do so may result in rejection of offers or other actions.

Amendment / Modification

• Option Year 2 is exercised, effective from February 15, 2025, through February 14, 2026.
• All other terms and conditions of the contract remain unchanged.

This modification exercises the option to extend the term of the contract.

This modification does not impact proposal submission deadlines or requirements as it exercises an option year.

Amendment / Modification

• Option 1 of the contract SPE2D2-23-D-0007 has been exercised.

• The period of performance for Option 1 is effective from February 15, 2024, through February 14, 2025.

• This modification exercises an option to extend the term of the contract, as authorized by FAR 52.217-9.

• This modification exercises an option and extends the contract period. It does not appear to change any submission requirements or deadlines for future solicitations.

Amendment / Modification

• This modification revises Solicitation page number 26, paragraph "17. Labeling" within the Statement of Work.

• It adds language requiring compliance with the Drug Supply Chain Security Act (DSCSA).

• Solicitation page 26, paragraph "17. Labeling" (Statement of Work).

• No changes to proposal deadlines or submission requirements are indicated. The modification focuses on labeling requirements for pharmaceutical products.

Amendment / Modification

This document is Modification P00002 to contract SPE2D2-23-D-0007, dated February 15, 2023. It modifies the contract to include the clause FAR 52.204-27, "Prohibition on a ByteDance Covered Application (JUN 2023)".

• The entire contract is modified to include the new clause.

• The modification prohibits the presence or use of a "covered application" (defined as TikTok or successor applications developed by ByteDance) on executive agency information technology, including equipment used by Federal contractors under this contract. This prohibition applies to information technology owned or managed by the Government, or information technology used or provided by the Contractor, including employee-provided equipment.

• An exception may be granted by the Contracting Officer via written notification.

• The Contractor is required to insert the substance of this clause into all subcontracts.

• Contractors who do not agree with this modification or are not in compliance must immediately notify the Contracting Officer in writing.

Amendment / Modification

• Revises the price effective date and ship date from April 16, 2023, to February 28, 2023.

• The modification impacts the price effective date and ship date.

• This modification does not appear to alter proposal deadlines or submission requirements, but it does change the effective dates for pricing and shipping.

Solicitation / RFP / RFQ

This document is a contract award (SPE2D2-23-D-0007) for Olopatadine HCL 0.1% Ophthalmic Solution (5ML bottles). The award is based on Solicitation SPE2D2-22-R-0117.

• Procurement of Olopatadine HCL 0.1% Ophthalmic Solution in 5ML bottles.

• The contract covers a Base Year and four Option Years.

• Contract Number: SPE2D2-23-D-0007

• Award/Effective Date: 02/15/2023

• Total Award Amount: $17,621,453.20 (estimated for 5 years)

• Annual Estimated Amount: $3,524,290.64

• Period of Performance: Base Year + 4 Option Years.

• Contract Type: Likely an Indefinite-Delivery/Indefinite-Quantity (IDIQ) or similar, given the "estimated" quantities and "option years."

• The document references "Final Proposal Revision dated 02/02/2023" and "response to negotiations" indicating a competitive solicitation process.

• Specific evaluation criteria are not detailed in this award document but were part of the original solicitation (SPE2D2-22-R-0117).

• The solicitation was initially an "RFP" (Request for Proposal).

• The document indicates various clauses related to small business concerns, including HUBZone, Service-Disabled Veteran-Owned Small Business, Women-Owned Small Business, and general small business set-asides, suggesting a focus on small business participation.

• The manufacturing and packaging of the product are performed by Apotex Inc. at their facility in Richmond Hill, Ontario, Canada.

• The contract incorporates numerous FAR and DFARS clauses, including those related to commercial items, small business concerns, and specific government requirements.

• Appendix A lists current Pharmaceutical Prime Vendors as of the solicitation date.